

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

InVivoMab anti-mouse CD28

RRID:AB_1107624

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0015-1, RRID:AB_1107624)

Antibody Information

URL: http://antibodyregistry.org/AB_1107624

Proper Citation: (Bio X Cell Cat# BE0015-1, RRID:AB_1107624)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: Agonistic Antibodies, in vivo Neutralization & Blocking

Antibody Name: InVivoMab anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: clone 37.51

Antibody ID: AB_1107624

Vendor: Bio X Cell

Catalog Number: BE0015-1

Alternative Catalog Numbers: BE0015-1-50MG, BE0015-1-1MG, BE0015-1-100MG, BE0015-1-5MG, BE0015-1-25MG

Record Creation Time: 20260114T193009+0000

Record Last Update: 20260623T051048+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse CD28.

No alerts have been found for InVivoMab anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 127 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cheng G, et al. (2026) Ablation of the adhesion G protein-coupled receptor ADGRL1 activates anti-tumor immune response via cDC1-T cell hub formation. *Cell reports*, 45(6), 117409.

Miller ML, et al. (2026) Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition. *Cell*, 189(6), 1717.

Yang D, et al. (2026) A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state. *Immunity*.

Meitei HT, et al. (2026) CCL20-CCR6 signaling alters the metabolic reprogramming to promote the pathogenic Th17 cell differentiation. *iScience*, 29(1), 114385.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Geng S, et al. (2026) Krüppel-like factor 2 programs early exhausted T cell states and restrains antiviral immunity. *Immunity*, 59(5), 1306.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. *Immunity*, 59(4), 1058.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

Sun JL, et al. (2026) Ferroptotic tumor cells reprogram tumor-associated macrophage antigen presentation to enhance the efficacy of immune checkpoint blockade. *Cell reports. Medicine*, 7(5), 102774.

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Yang D, et al. (2026) Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing ROR γ t and suppressing glucocorticoid receptor activity. *Immunity*.

Adhikari LP, et al. (2026) Naive CD4⁺ T cells synthesize a hyaluronan-rich glycocalyx that is diminished following activation. *iScience*, 29(7), 116407.

Lu Y, et al. (2025) Functional Genetic Screens Reveal Key Pathways Instructing the Molecular Phenotypes of Tumor-Associated Macrophages. *Cancer immunology research*, 13(12), 2054.

Shimba A, et al. (2025) Stress-induced glucocorticoids enhance acute inflammation by promoting the differentiation of Th17 cells. *Cell reports*, 44(8), 116093.

Wang Y, et al. (2025) Cognate interaction-dependent pathogenicity of meningeal B cells drives neuroinflammation relapse. *Immunity*, 58(9), 2256.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8⁺ T cells. *Immunity*, 58(10), 2472.

Ma Y, et al. (2025) TMEM41B is an endoplasmic reticulum Ca²⁺ release channel maintaining naive T cell quiescence and responsiveness. *Cell discovery*, 11(1), 18.

Zhang Y, et al. (2025) Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. *Cancer cell*, 43(9), 1677.